Open AccessIs Takotsubo syndrome in patients receiving chemotherapy drug-specific?
Author(s) -
John E. Madias
Publication year - 2015
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v3.i2.204
Subject(s) - medicine , chemotherapy , cytarabine , daunorubicin , drug , malignancy , myeloid leukemia , cardiomyopathy , leukemia , intensive care medicine , oncology , heart failure , pharmacology
In commenting on a case report of a 55-year-old man who suffered Takotsubo syndrome (TTS), in the setting of receiving chemotherapy with cytarabine and daunorubicin for acute myeloid leukemia, the author expresses his views that TTS in the setting of chemotherapy for malignancies may not be chemotherapeutic drug-specific (like in the chemotherapeutic drug induced-cardiomyopathy), but may be due to the emotional and physical stresses resulting from the realization of having diagnosed with a malignancy, and the diagnostic testing, and therapeutic management which follows.